Ultragenyx Pharmaceutical Inc. Logo

Email this page: News Release

Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders

For security reasons, registration is required before you can use this feature.
* Indicates required field